H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on CMPS stock, giving a Buy rating on December 10.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patrick Trucchio has given his Buy rating due to a combination of factors surrounding COMPASS Pathways’ upcoming Phase 3 data releases for COMP360. The anticipated readouts in 2026, particularly from the COMP006 and COMP005 trials, are expected to be pivotal in determining the regulatory and commercial trajectory of COMP360 in the treatment-resistant depression (TRD) market. These trials will provide critical insights into the efficacy, durability, and safety of the treatment, with the COMP006 trial focusing on a statistically significant difference in depression rating scales as a key regulatory hurdle.
Trucchio emphasizes the importance of the COMP005 26-week results in establishing long-term safety profiles, which will be crucial for clinical dosing paradigms. The combined data from these trials are anticipated to shape the regulatory framework and influence how clinicians and payers perceive the clinical value of COMP360. Given the strategic positioning of these trials and their potential to enhance the risk-benefit profile of COMP360, Trucchio reiterates a Buy rating and maintains a $40 price target for CMPS, viewing the Phase 3 programs as well-positioned for success.
In another report released on December 10, Oppenheimer also initiated coverage with a Buy rating on the stock with a $15.00 price target.